Previous 10 | Next 10 |
Deals and Financings Bio-Thera Solutions (SHA: 688177) of Guangzhou priced its IPO on Shanghai's STAR Board to raise $241 million at a valuation of almost $2 billion. The offering, which placed 60 million shares at RMB32.76 each, was reported to be 3,225 times oversubscribed. Bio-Thera lis...
BOSTON, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK ), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced the Company will host a conference call and live audio webcas...
Today, we will see why Sol-Gel Technologies ( SLGL ) is a promising small-cap dermatology pick for 2020. Company overview Sol-Gel Technologies Ltd. is a clinical-stage dermatology company focused on becoming leaders in the treatment of acne and rosacea. Sol-Gel Technologies has two inves...
An artist who is driven by money is no longer driven by art "― Jason E. Hodges Today, we look at a small healthcare concern in one of the most challenging parts of the biopharma space. This $3.50 antibiotic play signed a huge contract with BARDA in December which should derisk its ...
Antibiotics maker, Paratek Pharmaceuticals ( PRTK ), has struggled to hold onto gains in 2019. The has been a recent setback in the clinic but success on the funding front, both of which are worth discussing and the first focus of this article. Secondly, I look forward to a potential catalys...
Gainers: Southwest Georgia Financial (NYSEMKT: SGB ) +48% . More news on: Southwest Georgia Financial Corporation, Rite Aid Corporation, Paratek Pharmaceuticals, Inc., Stocks on the move, Read more ...
Paratek Pharmaceuticals (NASDAQ: PRTK ) +45% on BARDA contract for Nuzyra. More news on: Paratek Pharmaceuticals, Inc., Rite Aid Corporation, Catalyst Biosciences, Inc., Stocks on the move, Read more ...
Paratek Pharmaceuticals (NASDAQ: PRTK ) has been awarded a 5-year extendable contract , to support the development of NUZYRA (omadacycline) for the treatment of pulmonary anthrax, FDA post-marketing requirements (PMR) associated with the initial NUZYRA approval, and the option to procure up...
- Total award valued at up to $285 million - Paratek to host a conference call today, December 18, 2019 at 5:30 p.m. EST BOSTON, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the devel...
This article is part of a series that provides an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman’s regulatory 13F Form filed on 11/14/2019. Please visit our Tracking Seth Klarman’s Baupost Group Holdings...
News, Short Squeeze, Breakout and More Instantly...
Paratek Pharmaceuticals Inc. Company Name:
PRTK Stock Symbol:
NASDAQ Market:
Paratek Pharmaceuticals Inc. Website:
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Paratek Pharmaceuticals Inc. (PRTK) is expected to report $-0.25 for Q3 2023
BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military ...